Pembrolizumab Active in BCG-Unresponsive Papillary High-Risk Bladder Cancer

(MedPage Today) -- SAN FRANCISCO -- Pembrolizumab (Keytruda) monotherapy showed encouraging antitumor activity in patients with papillary high-risk non-muscle-invasive bladder cancer (HR NMIBC) that was unresponsive to Bacillus Calmette-Guerin...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news